Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:41 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Liver Transplant Recipients With Additional 12-month Follow-up and Long-term Extension
NCT03781414 · Novartis Pharmaceuticals · PHASE2 · terminated · last registry update 2025-05-16 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The study was terminated following less favorable efficacy by Iscalimab (CFZ533) in liver transplant patients compared to tacrolimus.” | – | Registry record, Novartis Pharmaceuticals |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against CD40 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-02-06Results posted on the registry: Novartis Pharmaceuticals, CFZ533 + Placebo to CFZ533 (NCT03827798)
- 2025-11-21Results posted on the registry: Hoffmann-La Roche, Nab-Paclitaxel + Gemcitabine (NCT03193190)
- 2025-11-21Results posted on the registry: M.D. Anderson Cancer Center, APX005M + Pembrolizumab (NCT02706353)
- 2025-11-21Also stopped (terminated): M.D. Anderson Cancer Center, APX005M + Pembrolizumab (NCT02706353)
- 2025-06-29Results posted on the registry: Novartis Pharmaceuticals, Iscalimab (NCT04541589)
- 2025-01-17Results posted on the registry: Novartis Pharmaceuticals, CFZ533 (NCT04129528)
- 2024-10-08Results posted on the registry: Washington University School of Medicine, CDX-301 + CDX-1140 (NCT04536077)
- 2024-10-08Also stopped (terminated): Washington University School of Medicine, CDX-301 + CDX-1140 (NCT04536077)
- 2024-07-18Results posted on the registry: Novartis Pharmaceuticals, CFZ533 + Placebo (NCT03610516)
- 2024-06-06Results posted on the registry: Novartis Pharmaceuticals, VAY736 + VAY736 Placebo (NCT03656562)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision